Anika Therapeutics (ANIK) Expected to Release Earnings on Wednesday

Anika Therapeutics (NASDAQ:ANIK) is expected to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect the company to post earnings of $0.03 per share and revenue of $29.2140 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:30 AM ET.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of ($0.07) by $0.34. Anika Therapeutics had a negative return on equity of 5.90% and a negative net margin of 9.52%.The firm had revenue of $29.61 million during the quarter, compared to analysts’ expectations of $28.14 million. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Anika Therapeutics Price Performance

ANIK opened at $14.95 on Monday. The company has a market capitalization of $198.98 million, a P/E ratio of -18.92 and a beta of 0.23. The firm’s fifty day moving average price is $14.98 and its two-hundred day moving average price is $13.53. Anika Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $16.49.

Wall Street Analyst Weigh In

ANIK has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anika Therapeutics in a report on Wednesday, June 24th. Wall Street Zen cut shares of Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $17.00.

Insider Buying and Selling

In other news, Director John B. Henneman III acquired 5,000 shares of Anika Therapeutics stock in a transaction on Friday, May 1st. The shares were purchased at an average price of $14.66 per share, with a total value of $73,300.00. Following the acquisition, the director owned 54,871 shares in the company, valued at $804,408.86. This represents a 10.03% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Stephen D. Griffin acquired 12,200 shares of the firm’s stock in a transaction on Thursday, April 30th. The stock was purchased at an average price of $12.29 per share, for a total transaction of $149,938.00. Following the completion of the transaction, the chief executive officer directly owned 36,163 shares in the company, valued at approximately $444,443.27. The trade was a 50.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 12.08% of the company’s stock.

Institutional Investors Weigh In On Anika Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP bought a new position in Anika Therapeutics in the second quarter valued at about $241,000. Nantahala Capital Management LLC acquired a new stake in Anika Therapeutics in the third quarter worth about $197,000. Jump Financial LLC bought a new stake in Anika Therapeutics during the 4th quarter worth about $193,000. Bridgeway Capital Management LLC bought a new stake in Anika Therapeutics during the 2nd quarter worth about $185,000. Finally, AQR Capital Management LLC acquired a new position in Anika Therapeutics during the 1st quarter valued at about $181,000. Institutional investors own 91.53% of the company’s stock.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.